Skip to main content

Advertisement

Table 1 Patient and tumor characteristics at baseline (N = 62)

From: FOLFIRI® and Bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms

  N (%)
Age (years)   
 Median 67.9  
 Range 60.4–75.4  
Sex   
 Male 25 (40.3)
 Female 37 (59.7)
ECOG performance status   
 0 20 (32.3)
 1 39 (62.9)
 2 3 (4.8)
Primary tumor location   
 Colon 53 (84.5)
 Rectum 9 (14.5)
Metastases   
 Liver 54 (87.1)
 Lung 28 (45.2)
 Lymph nodes 16 (25.8)
 Peritoneum 17 (27.4)
 Others 14 (22.5)
Number of organs involved (measurable)   
 1 8 (12.9)
 2 12 (19.3)
 ≥ 3 42 (66.1)
Adjuvant chemotherapy 17 (27.4)
Radiotherapy 8 (12.9)
Surgery 50 (80.6)